Rexulti (brexpiprazole) works by altering chemicals in the brain that can lead to schizophrenia or depression. Rexulti is an atypical antipsychotic medication approved to treat:

• schizophrenia
• symptoms of depression (major depressive disorder) when used with other medicines
• agitation associated with dementia due to Alzheimer’s disease.

Rexulti is classified as a serotonin-dopamine activity modulator (SDAM) and works at serotonin and dopamine receptors in the brain. It is considered a second generation version of aripiprazole (Abilify), but has slightly different activity at the serotonin and dopamine receptors which may reduce certain side effects such as restlessness.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death. Rexulti is not approved for the treatment of patients with dementia-related psychosis.

Safety and effectiveness of Rexulti in children have not been established.

Rexulti is given orally, once daily with or without food.

Note: Limitations of Use: Rexulti is not indicated as an as needed ("prn") treatment for agitation associated with dementia due to Alzheimer’s disease.

Related: Rexulti warnings, side effects, drug interactions

This is not all the information you need to know about Rexulti (brexpiprazole) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Rexulti information here, and discuss this information and any questions you have with your doctor or other health care provider.